Jul 10, 2025, 8:52 PM
Jul 10, 2025, 8:52 PM

FDA approves long-lasting injectable flea and tick treatment for dogs

Highlights
  • The FDA has approved a new injectable treatment for flea and tick prevention in dogs.
  • Bravecto Quantum provides up to 12 months of protection with a single injection.
  • This breakthrough offers significant convenience for dog owners, but requires veterinary supervision and monitoring.
Story

On Thursday, July 10, 2025, the U.S. Food and Drug Administration (FDA) approved a groundbreaking veterinary treatment for dogs, offering a new option for flea and tick prevention. The innovative treatment, known as Bravecto Quantum, is the first injectable option that provides up to 12 months of protection against these common parasites with a singular administration. This significant advancement allows dog owners to avoid the hassle of regular monthly or quarterly treatments, which has proven challenging for many pet owners, especially those living in areas with year-round parasite risks. Bravecto Quantum is intended for dogs and puppies aged six months and older, reflecting a shift in the approach to parasite control in canine care. The active ingredient, Fluralaner, is part of a well-established class of medications called isoxazolines, recognized for their safety and efficacy in veterinary use. However, this new injectable treatment must be administered by a licensed veterinarian, who will make determinations regarding whether an 8-month or a 12-month protection schedule is appropriate based on the local tick species present in the area. Veterinarians will also be tasked with monitoring for any potential side effects, although the medication is primarily considered safe. Some dogs may experience adverse reactions, including neurologic symptoms like muscle tremors and seizures, highlighting the necessity for appropriate veterinary oversight. Julie Cappiello from Voters For Animal Rights expressed cautious optimism about the new treatment, acknowledging its convenience while noting that not all medications are suitable for every dog, particularly those with prior neurological concerns. Manufactured by Intervet, Inc., based in Rahway, New Jersey, the introduction of Bravecto Quantum represents a notable advancement in veterinary parasitic control. Pet owners are encouraged to discuss this new option with their veterinarians to assess its suitability for their dogs, particularly for those living in regions that pose a higher risk for flea and tick infestations. By offering a long-term preventative solution, the FDA's approval is expected to be a game-changer for many dog owners, strengthening the partnership between pet owners and veterinarians in safeguarding the health of their canine companions.

Opinions

You've reached the end